Welcome to our dedicated page for Capricor Therapeutics news (Ticker: CAPR), a resource for investors and traders seeking the latest updates and insights on Capricor Therapeutics stock.
Capricor Therapeutics Inc (NASDAQ: CAPR) is a clinical-stage biotechnology leader advancing novel cell and exosome-based therapies for rare diseases. This dedicated news hub provides investors and researchers with essential updates on therapeutic developments, regulatory milestones, and scientific advancements.
Discover comprehensive coverage of CAP-1002 clinical progress for Duchenne muscular dystrophy, StealthXTM platform innovations, and strategic partnerships driving next-generation treatments. Our curated repository ensures access to verified press releases and objective reporting on critical developments in cardiac cell therapies and exosome delivery systems.
Key updates include clinical trial phases, peer-reviewed research publications, manufacturing advancements, and regulatory interactions. Bookmark this page for real-time tracking of Capricor's progress in redefining regenerative medicine through rigorous scientific validation and targeted therapeutic approaches.
Capricor Therapeutics has appointed Xavier Avat as Chief Business Officer to enhance its commercial strategy for CAP-1002, which targets Duchenne muscular dystrophy. With over 25 years of experience at leading biotech firms, Avat will oversee the commercialization of Capricor's products and business development initiatives. CEO Linda Marbán emphasized Avat's potential to drive growth and strengthen the company's positioning in rare diseases. Capricor is also expanding its proprietary exosome technology as part of its therapeutic portfolio.
Capricor Therapeutics (NASDAQ: CAPR) announced that CEO Dr. Linda Marbán will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022, in Miami, Florida. The presentation is scheduled for May 25, 2022, at 9:30 a.m. ET. Investors can register for the event through a provided link. Capricor, focused on developing transformative cell and exosome-based therapeutics, is advancing its lead candidate, CAP-1002, for Duchenne muscular dystrophy. The company aims to create exosomes for delivering nucleic acids to treat various diseases.
Capricor Therapeutics (NASDAQ: CAPR) announced a partnership with Nippon Shinyaku for the commercialization of CAP-1002 for Duchenne muscular dystrophy (DMD). The collaboration includes an upfront payment of $30 million and potential milestone payments up to $705 million. Positive Phase 2 results published in The Lancet confirm CAP-1002's efficacy in improving muscle function. The Phase 3 HOPE-3 trial is set to start this quarter, with about 70 patients expected to enroll across multiple sites. As of March 31, 2022, Capricor reported a net loss of $7.8 million, while cash reserves increased to $58.3 million.
Capricor Therapeutics (NASDAQ: CAPR) will announce its first quarter 2022 financial results on May 10, 2022, followed by a conference call at 4:30 p.m. ET. The company focuses on developing cell and exosome-based therapeutics for various diseases, with its lead candidate, CAP-1002, aimed at treating Duchenne muscular dystrophy. The call will discuss recent corporate updates and financial performance. A replay will be available post-broadcast. Investors can access the call via a toll-free number or a webcast link.
Capricor Therapeutics (NASDAQ: CAPR) announced that CEO Dr. Linda Marbán will participate in a panel discussion at the Cantor Fitzgerald Rare Orphan Disease Summit on March 30, 2022, at 4:00 p.m. ET. The panel will focus on cell therapy and its expanding definitions and applications for rare diseases. Capricor is a biotechnology company dedicated to developing cell and exosome-based therapeutics to address various diseases, including Duchenne muscular dystrophy and COVID-19 cytokine storms.
Capricor Therapeutics (NASDAQ: CAPR) announced that its Phase 2 INSPIRE study on CAP-1002 for severe COVID-19 met its primary safety objective. The study involved 63 patients, of whom 31% were admitted to ICU, and the mortality rate was 20%, with no significant difference between CAP-1002 and placebo groups. The CEO expressed optimism regarding safety outcomes and indicated ongoing analysis for next steps and potential partnerships. The trial represents an important exploration into CAP-1002's efficacy in treating serious COVID-19 symptoms.
Capricor Therapeutics (NASDAQ: CAPR) reported positive outcomes from the HOPE-2 Phase 2 trial of CAP-1002 for treating Duchenne muscular dystrophy (DMD). The study revealed significant improvements in skeletal and cardiac functions in non-ambulant patients after receiving CAP-1002, with a favorable safety profile. These results, published in The Lancet, support advancing to the HOPE-3 Phase 3 trial. Additionally, a partnership with Nippon Shinyaku enhances commercialization prospects.
Capricor Therapeutics (NASDAQ: CAPR) announced its fourth quarter and full year 2021 financial results, reporting a net loss of $6.2 million for Q4 and $20 million for the year. The company entered an exclusive partnership with Nippon Shinyaku for the commercialization of CAP-1002 for Duchenne Muscular Dystrophy, securing an upfront payment of $30 million and potential milestone payments of up to $705 million. The HOPE-3 Phase 3 trial for CAP-1002 is set to begin, and top-line data from the Phase 2 INSPIRE trial on COVID-19 is expected soon. Capricor's cash reserves stood at $34.9 million as of December 31, 2021.
Capricor Therapeutics (NASDAQ: CAPR) will announce its Q4 and full-year 2021 financial results on March 10, 2022, after market close. A conference call and webcast will follow at 4:30 p.m. ET. The company focuses on cell and exosome-based therapeutics, with its lead candidate, CAP-1002, in clinical development for Duchenne muscular dystrophy and COVID-19 complications. The webcast will be accessible 15 minutes prior to the call, and a replay will be available afterward.
Capricor Therapeutics (NASDAQ: CAPR) has appointed Dr. Daniel Paulson as Vice President of Clinical Development, focusing on the late-stage cell therapy program CAP-1002 and expanding the exosome platform. Dr. Paulson brings nearly 20 years of drug development experience, previously serving at Bayer AG and Sanofi. His expertise will aid in the potential commercialization of CAP-1002, targeting Duchenne muscular dystrophy and cytokine storm in COVID-19 patients. The company aims to advance its exosome technology for nucleic acid delivery in treating various diseases.
